Asymmetric catalysis. Production of chiral diols by enantioselective catalytic intramolecular hydrosilation of olefins
作者:Steven H. Bergens、Pedro Noheda、John Whelan、B. Bosnich
DOI:10.1021/ja00032a028
日期:1992.3
Rhodium(I) chiral diphosphine complexes efficiently and rapidly catalyze the intramolecular hydrosilation of silylethers derived fromallylicalcohols. The efficiency and rates of intramolecular hydrosilations were determined for a variety of silyl and olefin substituents. The catalysts were found to tolerate a widevariety of silyl substituents, although terminal alkyl olefin substituents were found to
Rhodium-Catalyzed Enantioselective Intramolecular CH Silylation for the Syntheses of Planar-Chiral Metallocene Siloles
作者:Qing-Wei Zhang、Kun An、Li-Chuan Liu、Yuan Yue、Wei He
DOI:10.1002/anie.201502548
日期:2015.6.1
Reported herein is the rhodium‐catalyzed enantioselectiveCH bond silylation of the cyclopentadiene rings in Fe and Ru metallocenes. Thus, in the presence of (S)‐TMS‐Segphos, the reactions took place under very mild conditions to afford metallocene‐fused siloles in good to excellent yields and with ee values of up to 97 %. During this study it was observed that the steric hindrance of chiral ligands
LIGAND-THERAPEUTIC AGENT CONJUGATES, SILICON-BASED LINKERS, AND METHODS FOR MAKING AND USING THEM
申请人:Albany Molecular Research, Inc.
公开号:US20160235858A1
公开(公告)日:2016-08-18
The present invention relates to ligand-therapeutic agent conjugate compounds, silicon linkers for the conjugate compounds, compositions, methods for making them, and methods for the treatment of cancer using the conjugate compounds. The silicon-based linkers described herein can be used to deliver desired therapeutic agents to particular cells or tissue types targeted by the ligand.
Ligand-therapeutic agent conjugates, silicon-based linkers, and methods for making and using them
申请人:Albany Molecular Research, Inc.
公开号:US09352049B2
公开(公告)日:2016-05-31
The present invention relates to ligand-therapeutic agent conjugate compounds, silicon linkers for the conjugate compounds, compositions, methods for making them, and methods for the treatment of cancer using the conjugate compounds. The silicon-based linkers described herein can be used to deliver desired therapeutic agents to particular cells or tissue types targeted by the ligand.